Friday, 15 May 2009

Kallidinogenase




Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C04AF01

CAS registry number (Chemical Abstracts Service)

0009001-01-8

Therapeutic Category

Vasodilator, peripheric

Chemical Name

Enzyme isolated from the pancreas or urine of mammals

Foreign Names

  • Kallidinogenasum (Latin)
  • Kallidinogenase (German)
  • Kallidinogénase (French)
  • Kalidinogenasa (Spanish)

Generic Names

  • Kalléone (OS: DCF)
  • Kallidinogenase (OS: JAN, BAN)
  • Angioxyl (IS)
  • Kallikrein (IS)
  • Kallidinogenase (PH: JP XV)

Brand Names

  • Cacelmin A
    Zensei Yakuhin, Japan


  • Cacelmin
    Zensei Yakuhin, Japan


  • Caltagon
    Guang Heng, Taiwan; Tsuruhara Seiyaku, Japan


  • Caluniatin S
    Nipro PharmaNipurofama, Japan; Wu Jang, Taiwan


  • Caluniatin
    Nipro PharmaNipurofama, Japan


  • Carnaculin
    Sanwa Kagaku, Japan


  • Circuletin S
    ASKA SeiyakuAsuka, Japan


  • Circuletin
    ASKA SeiyakuAsuka, Japan


  • Circulin S
    Showa Yakuhin Kako, Japan


  • Clermon
    Taiyo Pharmaceutical, Japan


  • Kalirechin S
    Kyowa Yakuhin, Japan


  • Kallikrein
    Tanabe Mitsubishi, Japan


  • Karikuromone
    Nichi-Iko PharmaceuticalJMA, Japan; S Nichi-Iko PharmaceuticalJMA, Japan


  • Kreislin
    Mikasa Seiyaku, Japan


  • Padutin
    Wabosan, Austria


  • Prokrein
    Tobishi, Japan


  • Promotin S
    Roman Industries, Japan


  • Rozagood
    Fujimoto, Taiwan; Fujimoto Seiyaku, Japan


  • Saymotin S
    Towa Yakuhin, Japan


  • S-Cardy
    Nisshin Seiyaku - Yamagata, Japan


  • Vasdolin F
    Kobayashi Kako, Japan


  • Vidokrein
    Tatsumi Kagaku, Japan

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment